NDAORAL-28TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORTHO-NOVUM 7/14-28 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1984.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 7/14-28 is an oral contraceptive combining ethinyl estradiol and norethindrone in a biphasic formulation delivered over a 28-day cycle. It prevents pregnancy through ovulation suppression and cervical mucus thickening. This product represents a foundational hormonal contraceptive from the 1984 approval era.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating brand team focus shifting toward generic transition planning and market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
No linked job postings currently available for ORTHO-NOVUM, reflecting its mature lifecycle stage and limited hiring for this legacy brand. Career opportunities would center on brand defense, generic transition management, and supply-chain efficiency rather than expansion or growth initiatives.
Brand Manager
Worked on ORTHO-NOVUM 7/14-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.